HS-10182, an EGFR Tyrosine Kinase Inhibitor, Increases Radiation Sensitivity in Non-Small Cell Lung Cancer With EGFR T790M Mutation

被引：0
|
作者：
Wang, Y. [1 ]
Chen, Y. [1 ]
Liu, N. [2 ]
Zhao, L. [3 ]
机构：
[1] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[2] Tianjin Med Univ, Canc Inst & Hosp, Dept Radiotherapy Oncol, Tianjin, Peoples R China
[3] Tianjin Med Univ, Canc Hosp & Inst, Tianjin, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2016年 / 96卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2016.06.1719
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3067
引用
收藏
页码：E433 / E433
页数：1
相关论文
共 50 条
  • [21] Novel third-generation pyrimidines-based EGFR tyrosine kinase inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
    An, Baijiao
    Liu, Jian
    Fan, Yangyang
    Nie, Wenyan
    Yang, Chunhua
    Yao, Han
    Li, Wei
    Zhang, Yin
    Li, Xingshu
    Tian, Geng
    BIOORGANIC CHEMISTRY, 2022, 122
  • [22] Managing EGFR T790M Mutation in Advanced Non-Small Cell Lung Cancers in THAILAND
    Prempree, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2136 - S2136
  • [23] Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR-Mutated Lung Cancer
    Haratake, Naoki
    Misumi, Toshihiro
    Yamanaka, Takeharu
    Seto, Takashi
    JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04):
  • [24] Clinical utility of repeated rebiopsy for EGFR T790M mutation detection in non-small cell lung cancer
    Lee, Eun Hye
    Kwak, Se Hyun
    Kim, Kyeong Yeon
    Kim, Chi Young
    Lee, Sang Hoon
    Heo, Seok-Jae
    Chang, Yoon Soo
    Kim, Eun Young
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [25] EGFR Tyrosine Kinase Inhibitor and Chemotherapy in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Nishino, Kazumi
    Kimura, Madoka
    Inoue, Takako
    Uchida, Junji
    Kumagai, Toru
    Imamura, Fumio
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S526 - S526
  • [26] An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer
    Wang, Jingyi
    Wu, Lin
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (06) : 647 - 652
  • [27] Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Khozin, Sean
    Weinstock, Chana
    Blumenthal, Gideon M.
    Cheng, Joyce
    He, Kun
    Zhuang, Luning
    Zhao, Hong
    Charlab, Rosane
    Fan, Ingrid
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2131 - 2135
  • [28] Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Skoulidis, Ferdinandos
    Papadimitrakopoulou, Vassiliki A.
    CLINICAL CANCER RESEARCH, 2017, 23 (03) : 618 - 622
  • [29] The Usefulness of "Serum" Samples to Detect EGFR T790M Mutation in EGFR-TKI-Resistant Non-Small Cell Lung Cancer
    Kobayashi, K.
    Naoki, K.
    Ikemura, S.
    Yasuda, H.
    Kawada, I.
    Soejima, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S936 - S937
  • [30] Clinicopathological Characteristics of Non-small Cell Lung Cancer Patients With Primary Concomitant EGFR T790M Mutation
    Li, Hang
    Wang, Rui
    Hu, Haichuan
    Pan, Yunjian
    Wang, Lei
    Zhang, Yang
    Sun, Yihua
    Chen, Haiquan
    CHEST, 2014, 145 (03)
12345